Transaction details
Glen Taylor, cited in regulatory filings as a 10% owner of Envoy Medical, Inc. (NASDAQ: COCH), executed a purchase of 18,750,000 shares of the company’s Class A Common Stock at $0.40 per share. The total consideration for that block was $7,500,000, and the transaction is recorded on a Form 4 filed with the Securities and Exchange Commission as taking place on February 12, 2026. The $0.40 purchase price compares to a contemporaneous trading price of $0.67 and follows a 53.89% return in the stock over the prior week.
Post-transaction ownership
Following the acquisition, Taylor directly holds 21,703,607 shares of Class A Common Stock. The same filing notes additional securities acquired the same day: 11,250,000 Warrant Shares (Series A-1) and 18,750,000 Warrant Shares (Series A-2), each obtained at a stated price of $0.00. The filing also identifies indirect holdings: 2,526,058 shares owned through Taylor Sports Group and 4,810,384 shares held via GAT Funding, LLC.
Clinical program status
Separately from the equity transaction, Envoy Medical reports it has reached the midway point in enrolling patients in the pivotal clinical study of its investigational, fully implanted Acclaim cochlear implant. The company stated that, although holiday scheduling presented challenges, multiple sites remain actively screening candidates. Envoy expects to complete full enrollment within the first half of the first quarter of 2026.
Intellectual property update
Envoy has also been awarded Australian Patent No. 2022229818, issued October 16, 2025. The patent covers innovations tied to an input source that includes a sensor and a powered signal modifier incorporating an amplifier. The described technology is intended to improve the signal-to-noise ratio in cochlear implant systems by amplifying acoustic signals at the input source.
Context and next steps
The Form 4 filing documents the equity and warrant acquisitions and the updated ownership figures. The clinical enrollment milestone and the patent grant were presented by the company as ongoing developments in its program to advance hearing health solutions. The company’s stated enrollment timeline and the granted patent remain points to watch as the study proceeds and the firm continues development of its Acclaim system.
Note: Information in this article is based on the company filings and updates cited above.